Comparative Pharmacology
Head-to-head clinical analysis: ASPIRIN OMEPRAZOLE versus PREVACID 24 HR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPIRIN OMEPRAZOLE versus PREVACID 24 HR.
ASPIRIN; OMEPRAZOLE vs PREVACID 24 HR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aspirin irreversibly acetylates cyclooxygenase (COX-1 and COX-2), inhibiting thromboxane A2 synthesis and platelet aggregation. Omeprazole is a proton pump inhibitor that irreversibly binds to H+/K+-ATPase in gastric parietal cells, reducing gastric acid secretion.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+-ATPase enzyme system (proton pump) at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
Aspirin 81 mg orally once daily plus omeprazole 20 mg orally once daily.
15 mg orally once daily for 14 days.
None Documented
None Documented
Aspirin: 15-20 minutes for parent drug; salicylate half-life 2-3 hours at low doses, increasing to >20 hours at high doses due to saturable hepatic metabolism; clinically, dosing interval adjusted for antiplatelet effect (low dose) vs anti-inflammatory (high dose). Omeprazole: 0.5-1 hour; no accumulation on repeated dosing; metabolized via CYP2C19 and CYP3A4.
1.2-1.5 hours in healthy subjects; no accumulation with once-daily dosing.
Aspirin: renal elimination of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid); ~10% excreted unchanged in urine; dose-dependent due to saturable metabolism. Omeprazole: ~80% eliminated as metabolites in urine, ~20% in feces via biliary excretion.
Approximately 66% renal (as metabolites), 33% fecal (primarily biliary); less than 1% unchanged in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor